Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab vs penpulimab plus chemotherapy as neoadjuvant therapy for resectable NSCLC
ChiCTR2500108304Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Ivonescimab plus chemotherapy with Penpulimab plus chemotherapy (2 arms). Primary endpoint: Pathologic complete response rate (pCR). Started Aug 2025; status: recruiting.
02
Drugs
ivonescimabpenpulimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500108304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108304.